Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients

Gunes, Arzu; Scordo, Maria Gabriella; Jaanson, Peeter; Dahl, Marja­‐Liisa

doi:10.1007/s00213-006-0622-x

Cited by 63 publications

(50 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[29][30][31] However, in our sample, no association with EPS was observed for this polymorphism, which is consistent with the earlier reports in the literature. 32,33 Interestingly, the same common variant in DRD3 associated with AP-induced EPS in our study, rs167771, was associated with autism spectrum disorder (ASD) in a two-stage design association study analyzing 1536 SNPs. 34 The selection of SNPs in both the present study and the study of de Krom et al 34 was very similar.…”

Section: Discussionmentioning

confidence: 53%

“…First, the sample size (n ¼ 270), though limited, was higher than the mean sample size used in pharmacogenetic studies of acute AP-induced EPS (n ¼ 150). [7][8][9][10]32,33,[35][36][37][38][39][40][41][42][43][44][45] In fact, to our knowledge, only one study of Caucasians had a larger sample (n ¼ 665). 36 Second, although Bonferroni correction seems the most appropriate way to correct for multiple testing, it may be overly conservative.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms

et al. 2009

View full text Add to dashboard Cite

We present a pharmacogenetic study of acute antipsychotic (AP)-induced extrapyramidal symptoms (EPS) using an extensive linkage disequilibrium mapping approach in seven-candidate genes with a well-established link to dopamine (DRD2, DRD3, ACE, COMT, DAT, MAO-A, MAO-B). From a cohort of 321 psychiatric inpatients, 81 cases presenting with EPS (Simpson-Angus 43) and 189 controls presenting without EPS (Simpson-Angus p3) took part. Eighty-four-tag single nucleotide polymorphisms (SNPs) in candidate genes were genotyped. After extensive data cleaning, 70 SNPs were analyzed for association of single markers and haplotypes. AP dosage, AP-DRD2 blockade potency and age were identified as susceptibility factors for APinduced EPS. One SNP of the DRD3 gene, rs167771, achieved significant association with EPS risk after Bonferroni correction (nominal P-value 1.3 Â 10 À4 ) in the patients treated with risperidone (132 patients). APinduced EPS remains a serious public health problem. Our finding of a common SNP (rs167771) in the DRD3 gene provides a strong new candidate gene for risperidone-induced EPS.

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 92%

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Например, P. Eichhammer и соавт. [76] сообщили об учащении раз-вития акатизии среди носителей аллеля Gly, однако два других исследования [77,78] дали в этом отношении от-рицательные результаты.…”

Section: дофаминергическая системаunclassified

“…Тем не менее в некоторых более поздних иссле-дованиях [44,100,101], проведенных в трех различных эт-нических группах (индийцы, афро-карибская этническая группа и американцы смешанных национальностей) эти данные не были подтверждены. Параллельно аллель С по-лиморфизма T102C исследовался в плане риска развития острых экстрапирамидных нарушений при проведении антипсихотической терапии [102]. Были получены также положительные результаты относительно ассоциации ри-ска развития поздней дискинезии с носительством поли-морфизма -1438G/A гена HTR2A и Cys23Ser в HTR2C.…”

Section: серотонинергическая системаunclassified

Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms

Сосин

et al. 2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

“…Particularly 5-HT 1A , 5-HT 2A/2C and 5-HT 3 receptor signalling seems to be altered in TD. Recently, a possible genetic predisposition to develop TD exists, and association between TD and receptor gene polymorphisms of 5-HT 2A and 5-HT 2C genes has actually been shown (Gunes et al, 2007(Gunes et al, , 2008.…”

Section: Role Of 5-ht In Apd-induced Extrapyramidal Side Effectsmentioning

confidence: 99%

Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders

Matteo

Pierucci

Esposito

et al. 2008

Progress in Brain Research

138

View full text Add to dashboard Cite

Several recent studies have emphasized a crucial role for the interactions between serotonergic and dopaminergic systems in movement control and the pathophysiology of basal ganglia. These observations are supported by anatomical evidence demonstrating large serotonergic innervation of all the basal ganglia nuclei. In fact, serotonergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high concentration of serotonin (5-HT), with the substantia nigra pars reticulata receiving the greatest input. In this chapter, the distribution of different 5-HT receptor subtypes in the basal ganglia nuclei will be described. Furthermore, evidence demonstrating the serotonergic control of basal ganglia activity will be reviewed and the contribution of the different 5-HT receptor subtypes examined. The new avenues that the increasing knowledge of 5-HT in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. It is clear that these avenues will be fruitful, despite the disappointing results so far obtained by clinical studies with selective 5-HT ligands. Nevertheless, these studies have led to a great increase in the attention given to the neurotransmitters of the basal ganglia and their connections.

show abstract

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients

Abstract: An association was observed between polymorphisms in HTR2A and HTR2C genes and occurrence of acute EPS in schizophrenic patients treated with perphenazine monotherapy. Larger study populations are needed to confirm our findings.

Cited by 63 publications

References 41 publications

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms

Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms

Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders

Contact Info

Product

Resources

About